Celgene (NASDAQ:CELG) is an American pharmaceutical stock which, in my opinion, has the most potential to grow out of any other large pharmaceutical company in the industry. Its blockbuster drug, Revlimid, has seen consistent double-digit revenue growth every year. CELG also has a large and strong pipeline with many different drugs which could become blockbuster drugs. The main 4 main drugs which are driving revenue for Celgene are Revlimid, Pomalyst, Otezla and Abraxane. Three of them have over a billion dollars in sales annually with Abraxane expected to exceed a billion dollars in 2017. These 4 revenue drivers are also all patent protected to at least 2022 (most of them are protected for longer than 2022). Revlimid will have patent protection until 2027 in the US.
Celgene Is A Must-Own Stock
4/27/17
Stories you Need to Know
- David Nevins Interviews Dr. Matthew Frieman, Associate Professor, University of Maryland School of Medicine
- Amneal Reports Fourth Quarter and Full Year 2020 Financial Results
- Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Provention Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
- Pacira BioSciences Reports Full-Year and Fourth Quarter 2020 Financial Results
- MTBC Reports Record Full Year 2020 Results
- Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
- Merck to Acquire Pandion Therapeutics
- Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights

